Oncolytics Biotech (ONCY) Tops Q1 Loss Views by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts ONCY Hot Sheet
Join SI Premium – FREE
Oncolytics Biotech (NASDAQ: ONCY) reported Q1 loss of ($0.06), $0.03 better than the analyst estimate of ($0.09).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer
- Getty Realty (GTY) Tops Q3 EPS by 5c
- Nokia (NOK) Tops Q3 EPS by 2c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
